CenterBook Partners LP Raises Stake in BioNTech SE (NASDAQ:BNTX)

CenterBook Partners LP boosted its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 62.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 194,118 shares of the company's stock after purchasing an additional 74,656 shares during the quarter. BioNTech comprises 1.3% of CenterBook Partners LP's investment portfolio, making the stock its 9th largest holding. CenterBook Partners LP owned 0.08% of BioNTech worth $22,120,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC increased its stake in BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock valued at $4,726,000 after buying an additional 33,375 shares during the period. Mirabaud & Cie SA purchased a new position in BioNTech during the fourth quarter worth about $684,000. Bank of New York Mellon Corp boosted its holdings in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after purchasing an additional 150 shares in the last quarter. Vestcor Inc purchased a new position in shares of BioNTech during the 3rd quarter worth approximately $784,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in BioNTech during the fourth quarter worth $1,118,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several research analyst reports. Citigroup initiated coverage on BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 price objective for the company. BMO Capital Markets boosted their target price on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Truist Financial started coverage on shares of BioNTech in a research report on Friday, January 10th. They set a "buy" rating and a $172.00 target price on the stock. HC Wainwright lowered their price objective on BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $143.44.

Remove Ads

BioNTech Stock Up 5.6 %

Shares of NASDAQ BNTX traded up $5.38 during mid-day trading on Monday, reaching $101.90. The company had a trading volume of 782,345 shares, compared to its average volume of 855,212. The company has a market capitalization of $24.45 billion, a price-to-earnings ratio of -48.52 and a beta of 1.07. The stock has a fifty day moving average of $104.64 and a two-hundred day moving average of $111.63. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The business's quarterly revenue was down 19.5% compared to the same quarter last year. As a group, equities research analysts expect that BioNTech SE will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.